Marion Webb has been writing about medtech since 2017, specializing in covering buzzy segments such as robotic surgery, digital therapeutics and femtech with in-depth features and interviews with leading experts. Her role includes reporting live from industry events, moderating panel discussions and podcasts, tweeting breaking news and engaging KOLs to provide high-quality, business-critical content for Medtech Insight. Marion has been writing about health care issues for more than two decades. She was a long-time biotech reporter at the San Diego Business Journal, worked at Bloomberg News, and contributed to the Los Angeles County Medical Association’s Physician Magazine. Marion was born and raised in Germany, is fluent in German and conversational in Spanish. Off the job, she’s a competitive runner, avid cyclist and swimmer, and enjoys spending time with her domestic partner and her German Shorthair Pointer mix Cora.
Latest from Marion Webb
Truvian reached a major milestone with the FDA clearance of its blood-testing benchtop but is awaiting further FDA clearances of blood panels before a full launch in the second half of 2026.
Paradromics won FDA clearance to test its Connexus BCI in two people with severe speech impairment. The 2026 trial will assess whether the device can decode speech in real time.
Medtech Insight spoke with Rambam Medical Center’s Michael Mimouni, who implanted the first 3D-bioprinted corneal graft in a human patient, about his hopes for Precise Bio’s approach. The patient is part of a Phase I trial evaluating PB-001 in patients with corneal edema.
Medtech funding in 2025 sees a trend of fewer, yet larger deals with total funding of $3.6bn in Q1, $2.6bn in Q2 and $2.9bn in Q3, said LSI’s Nick Talamantes. In 2026, he expects a continued investor focus on more mature firms in areas of oncology, cardiology and neurology.
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
BrainsWay advanced its Deep TMS platform with an FDA labeling expansion for adolescent MDD and the launch of a 200-patient alcohol use disorder trial. The company posted strong Q3 growth and is pursuing new indications and at-home neuromodulation through its Neuralief investment.